skip navigation

Test Identifier Information

Registration CodeCOQ

HPLC with electrochemical detector.

External Price$91.00(Exclusive of GST)

Specimen Collection

Pre-Testing Requirements


Patient Specimen5 mL Heparin(Green)
Paediatric Specimen1 mL Heparin(Green)
Sample Delivery to LabAmbient

Instructions for Referral to CHLabs

Aliquot Instructions>0.3 mL plasma. Frozen. Protect from light.
Aliquot Transport to CHLFrozen.

CHLabs Laboratory

DepartmentBiochemistry - Specialist
Contact Details Email Email
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Contact Phone Number(03) 364 0332 | x80332
Test AvailabilityContact Analytical laboratory.
Turnaround Time21 days
Reference Interval

Reference Range 0.5 - 1.8 umol/L


Coenzyme Q10

Coenzyme Q10 (CoQ10) is a quinone, consisting of an aromatic head group with a hydrophobic tail of 10 isopreniod units. Coenzyme Q also occurs with less than 10 isoprenoid units in the tail, but 10 is found in humans. Within the body, CoQ10 is found in both the reduced and oxidised forms..
Coenzyme Q10 is essential to life, acting as a mobile electron carrier in the mitochondrial electron transport chain. This chain is essential for the production of adenosine triphosphate (ATP). In this chain, coenzyme Q10 shuttles electrons between complexes III and II, and I and II. To complete this transfer of electrons, coenzyme Q10 shuttles between the oxidised form (ubiquinone), a semiquinone form, and the reduced form (ubiquinol). This is hence why both the reduced and oxidised forms are found in the human body. The majority of CoQ10 in the body is in the reduced form (about 96% of total CoQ10 or higher).
Coenzyme Q10 is transported in the blood in low density lipoproteins (LDL). Reduced CoQ10 can also act as an antioxidant, and therefore it is accepted that CoQ10 aids in protection of LDL from oxidation. Coenzyme Q10 may therefore protect the human body from heart disease by inhibiting oxidation of LDL and subsequent formation of fatty plaques in arteries.
The human body synthesises coenzyme Q10 in the liver, from aromatic amino acids and acetyl-CoA. This synthesis pathway is often referred to as the mevalonate pathway, and is also the pathway by which cholesterol is synthesised in the body. It is therefore not surprising that statins, drugs which inhibit the mevalonate pathway, and which are prescribed to lower cholesterol levels, can also inhibit synthesis of CoQ10 in the body. Some CoQ10 is also obtained from the diet, where meats are an especially good source.
Primary deficiency of CoQ10- is a rare autosomal recessive dissorder, with symptoms of ataxia and myopathy. A secondary CoQ10 deficiency occurs in patients receiving statin therapy, and this is expected to be the main reason for CoQ10 requests. Some statin-induced myopathies have been attributed to an induced CoQ10 deficiency.

Additional Information

Serum and EDTA are unacceptable sample types. 

Delphic Number Test Number4868

CHL Follow us on Facebook